Derma Sciences to Showcase MEDIHONEY® and TCC-EZ® at Novation Innovative Technology Expo

Annual event highlights new technology that increases safety and improves patient outcomes

Business Wire

PRINCETON, N.J.--(BUSINESS WIRE)--

Derma Sciences, Inc. (DSCI), a medical device and pharmaceutical company focused on advanced wound care, is showcasing its MEDIHONEY® line of advanced wound care dressings and its TCC-EZ® Total Contact Casting system at the Novation Innovative Technology Expo today at the Irving Convention Center in Las Colinas, TX. The event provides medical technology suppliers the opportunity to gain direct feedback from onsite clinical experts and healthcare providers on the impact their products have on improving patient care and reducing the risk of harm to patients and caregivers.

MEDIHONEY is the global leading line of medical-grade honey products for the management of wounds and burns. Derived from the Leptospermum scoparium species of plant in New Zealand, these unique dressings have properties that are beneficial throughout all phases of wound healing. MEDIHONEY offers a full line of dressing solutions, providing versatility for varying wound conditions and wound management needs. MEDIHONEY was recognized by Novation as a finalist for the 2011 Innovative Technology Award and was selected as a finalist by Novation members, based on the product's impact on patient care and improving patient outcomes.

Total Contact Casting is recognized as the Gold Standard of care for diabetic foot ulcers. TCC-EZ offers a one-piece, roll-on, woven design that simplifies the casting while reducing the potential for causing additional tissue damage. The application process can be completed in less than 10 minutes while providing greater patient comfort.

“We are delighted once again to be participating in Novation’s Innovative Technology Expo, and are pleased that Novation has provided us with the opportunity to showcase the attributes of our two advanced wound care anchor product lines,” said Barry Wolfenson, Group President, Advanced Wound Care and Pharmaceutical Development of Derma Sciences. “We have a long and productive relationship with Novation and are very pleased that MEDIHONEY is under an Innovative Technology agreement. We are also pleased to have submitted TCC-EZ as a novel technology in helping to advance patient care for diabetic foot ulcers, and are hopeful to receive our second Innovative Technology Award.”

Participating companies include those who have submitted products for evaluation or have already been awarded a contract by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the 65,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association and Provista LLC.

Since 2003, more than 1,500 new and innovative technologies have been submitted through the Novation Innovative Technology program. Novation works with member-led councils and task forces to identify and review potentially innovative technology. Once these teams have evaluated the technology and determined that it provides an incremental clinical benefit over existing products, a contract for the innovative technology may be awarded outside of Novation's competitive bid cycle.

To learn more about Novation's Innovative Technology program, visit www.novationco.com/expertise/technology.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun Phase 3 clinical trials in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention.

For more information please visit www.dermasciences.com.

About Novation, Winner of the Ethics Inside® Certification

Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 65,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children’s Hospital Association, an alliance of the nation’s leading pediatric facilities, and Provista, LLC. Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase approximately $43 billion in 2012. Novation has earned the coveted Ethics Inside® Certification from Ethisphere Institute, a leading international think tank dedicated to the research and promotion of best practices in corporate ethics and compliance. Novation also was named on Ethisphere’s World’s Most Ethical Companies list, and is the only company in the health care industry to earn both distinctions for two consecutive years. To learn more about Novation, please visit www.novationco.com and follow @NovationNews.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission.

Contact:
Derma Sciences, Inc.
Barry Wolfenson, 609-514-4744
Group President, Advanced Wound Care and Pharmaceutical Development
bwolfenson@dermasciences.com
or
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Rates

View Comments (0)